NDAINHALATIONGAS
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
5/8 — Partial
Carbon Dioxide, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. Approved for actinic keratosis. First approved in 2024.
Drug data last refreshed 20h ago
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Clinical Trials (16)
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Started Dec 2025
99 enrolled
Acute Respiratory Distress SyndromeAcute Kidney Injury
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Started Feb 2024
15 enrolled
ARDS, Human
Carbon Dioxide Investigation
Started Jan 2024
42 enrolled
IntubationTracheostomyLaryngeal Mask
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
Started Nov 2023
29 enrolled
Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Started Mar 2023
1 enrolled
Carbon Dioxide LaserPhotoaging
Worked on Carbon Dioxide, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.